Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ardelyx (ARDX): RA Capital Management Boosts Stake to 7.7%

Page 1 of 7

Peter Kolchinsky‘s RA Capital Management has stepped up its interest in Ardelyx Inc. (NASDAQ:ARDX). As reported in a recent filing with the Securities and Exchange Commission, the fund now holds 3.46 million shares of the stock, plus warrants to acquire an additional 168,225 shares, giving it economic exposure to 7.7% of Ardelyx’s common stock. At the end of March, RA Capital reportedly held 2.3 million shares.

Founded in 2007, Ardelyx Inc. (NASDAQ:ARDX) engages in the research and development of minimally-systemic therapeutics for the treatment of gastrointestinal and cardio-renal diseases. Tenapanor, the company’s top candidate, is currently undergoing Phase 3 trials and has so far demonstrated efficiency in reducing the absorption of dietary sodium and phosphorus, which are key factors in some kidney diseases. The first results from the trials are expected in 2017. The recently agreed-upon takeover of Relypsa Inc (NASDAQ:RLYP) by Galenica has sparked speculation that Ardelyx might be next in line for a takeover, as Relypsa’s top drug, Veltassa, has properties similar to those of Ardelyx’s candidates.

BPMC

At the end of the first quarter, approximately 17% of Ardelyx Inc. (NASDAQ:ARDX)’s common stock was held by nine of the funds tracked by Insider Monkey, up from seven long positions registered three months earlier. Bihua Chen‘s Cormorant Asset Management was also invested in this stock, having indicated ownership of 1.48 million shares of it in its latest 13F filing. James E. Flynn‘s Deerfield Management established a fresh position in the stock during the first quarter, having amassed 275,000 Ardelyx shares by the end of March.

Follow Ardelyx Inc. (NASDAQ:ARDX)
Trade (NASDAQ:ARDX) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 3,625,943 0 3,625,943 3,625,943 7.7%
Peter Kolchinsky 0 3,625,943 0 3,625,943 3,625,943 7.7%
RA Capital Healthcare Fund 0 2,451,968 0 2,451,968 2,451,968 5.2%
Peter Kolchinsky
Peter Kolchinsky
RA Capital Management

Page 1 of 7 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of
1934

 

(Amendment No. __)*


ARDELYX, INC.

 (Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

039697107

(CUSIP Number)

 

July 18, 2016

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Page 1 of 7

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!